Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).

Abstract

Aluminum-related osteomalacia has been a topic of major interest for some time. Patients on dialysis who are affected exhibit reduced parathyroid function and osteomalacia associated with high levels of aluminum in the extracellular fluid and tissues. In bone, aluminum is found in the interface between mineralized and nonmineralized osteoid. In the present study we attempted treatment of the aluminum-related bone disease with DFO, a potent chelating agent. A thyroparathyroidectomized patient on hemodialysis with proven osteomalacia and aluminum deposits in bone received DFO 3 times/week for 1 year. Consequently, there was a marked improvement in his skeletal status, both clinically and histologically. This was associated with aluminum deposits within the mineralized component of bone as well as elevated parathyroid function measured in blood and bone. These findings suggest that calcification may occur despite the presence of aluminum in the mineralizing front. The main beneficial effect of DFO could be relief of the inhibitory action of aluminum on parathyroid cells and osteoblasts.

• Authors: J Rapoport, C Chaimovitz, A Abulfil, M Mostovlavsky, D Gazit, I Bab
• Journal: Israel journal of medical sciences (Isr J Med Sci) Vol. 23 Issue 12 Pg. 1242-6 (Dec 1987) ISSN: 0021-2180 [Print] Israel
• PMID: 3440748 (Publication Type: Case Reports, Journal Article)

Chemical References

• Aluminum
• Deferoxamine

Topics

• Adult
• Aluminum (adverse effects)
• Biopsy
• Bone and Bones (pathology)
• Deferoxamine (therapeutic use)
• Humans
• Male
• Osteomalacia (drug therapy, etiology, pathology)
• Renal Dialysis (adverse effects)